お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
市場調査レポート
商品コード
966708

ナチュラルキラー (NK) 細胞リンパ腫:市場考察・疫学・市場予測 (~2030年)

Natural Killer (NK)-Cell Lymphoma - Market Insight, Epidemiology and Market Forecast - 2030

出版日: 受注後作成 | 発行: DelveInsight Business Research LLP | ページ情報: 英文 200 Pages | 納期: 約10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=107.49円
ナチュラルキラー (NK) 細胞リンパ腫:市場考察・疫学・市場予測 (~2030年)
出版日: 受注後作成
発行: DelveInsight Business Research LLP
ページ情報: 英文 200 Pages
納期: 約10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、米国、欧州5ヶ国(ドイツ、スペイン、イタリア、フランス、英国)、および日本の7つの主要市場におけるナチュラルキラー (NK) 細胞リンパ腫市場について詳細に説明し、SWOT分析、疾患のリスクと負担、アンメットニーズ、有病率の高い症例、診断数・治療数などに関する情報を提供しています。

目次

第1章 主な洞察

第2章 ナチュラルキラー (NK) 細胞リンパ腫のエグゼクティブサマリー

第3章 ナチュラルキラー (NK) 細胞リンパ腫の競合分析

第4章 ナチュラルキラー (NK) 細胞リンパ腫:市場概要

  • ナチュラルキラー (NK) 細胞リンパ腫の総市場シェア(%)分布
  • ナチュラルキラー (NK) 細胞リンパ腫の総市場シェア(%)分布予測

第5章 ナチュラルキラー (NK) 細胞リンパ腫:疾患の背景と概要

  • イントロダクション
  • 徴候と症状
  • 病態生理学
  • 危険因子
  • 診断

第6章 ペイシェントジャーニー

第7章 ナチュラルキラー (NK) 細胞リンパ腫の疫学と患者人口

  • 主な調査結果
  • 仮定と理論的根拠:主要7ヶ国
  • 疫学シナリオ:主要7ヶ国
    • 主要7ヶ国におけるナチュラルキラー (NK) 細胞リンパ腫の疫学シナリオ
  • 米国の疫学
    • 米国におけるナチュラルキラー (NK) 細胞リンパ腫の疫学シナリオ
  • 欧州5ヶ国の疫学:国別
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国
    • 日本

第8章 治療アルゴリズム、現在の治療法、および医療行為

  • 治療と管理
  • 治療アルゴリズム

第9章 アンメットニーズ

第10章 主要なエンドポイント

第11章 市販薬

  • 主要7ヶ国で販売されている製品のリスト
  • 医薬品名:企業名
    • 製品説明
    • 規制のマイルストーン
    • その他の開発活動
    • 重要な臨床試験
    • 重要な臨床試験の概要

第12章 新たな治療法

  • 主な競合
  • 医薬品名:企業名
    • 製品説明
    • その他の開発活動
    • 臨床開発
    • 安全性と有効性
    • 製品プロファイル

第13章 ナチュラルキラー (NK) 細胞リンパ腫:主要7市場の分析

  • 主な調査結果
  • 主要7ヶ国におけるナチュラルキラー (NK) 細胞リンパ腫の市場規模
  • 主要7ヶ国におけるナチュラルキラー (NK) 細胞リンパ腫の市場規模:治療別

第14章 属性分析

第15章 主要7ヶ国:市場の見通し

  • 米国:市場規模
    • 米国におけるナチュラルキラー (NK) 細胞リンパ腫の総市場規模
    • 米国におけるナチュラルキラー (NK) 細胞リンパ腫の市場規模:治療法別
  • 欧州5ヶ国カ国:市場規模と展望
  • ドイツの市場規模
    • ナチュラルキラー (NK) 細胞リンパ腫の総市場規模
    • ナチュラルキラー (NK) 細胞リンパ腫の市場規模:治療法別
  • フランスの市場規模
  • イタリアの市場規模
  • スペインの市場規模
  • 英国の市場規模
    • ナチュラルキラー (NK) 細胞リンパ腫の総市場規模
    • ナチュラルキラー (NK) 細胞リンパ腫の市場規模:治療法別
  • 日本市場の見通し
    • 日本の市場規模

第16章 ナチュラルキラー (NK) 細胞リンパ腫のアクセスと医療費償還の概要

第17章 KOL の見解

第18章 市場の促進要因

第19章 市場の障壁

第20章 付録

  • 参考文献
  • レポートの調査手法

第21章 DelveInsightのサービス内容

第22章 免責事項

第23章 DelveInsightについて

図表

List of Tables

  • Table 1: 7MM Natural Killer (NK)-Cell Lymphoma Epidemiology (2017-2030)
  • Table 2: 7MM Natural Killer (NK)-Cell Lymphoma Diagnosed and Treatable Cases (2017-2030)
  • Table 3: Natural Killer (NK)-Cell Lymphoma Epidemiology in the United States (2017-2030)
  • Table 4: Natural Killer (NK)-Cell Lymphoma Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5: Natural Killer (NK)-Cell Lymphoma Epidemiology in Germany (2017-2030)
  • Table 6: Natural Killer (NK)-Cell Lymphoma Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7: Natural Killer (NK)-Cell Lymphoma Epidemiology in France (2017-2030)
  • Table 8: Natural Killer (NK)-Cell Lymphoma Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9: Natural Killer (NK)-Cell Lymphoma Epidemiology in Italy (2017-2030)
  • Table 10: Natural Killer (NK)-Cell Lymphoma Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11: Natural Killer (NK)-Cell Lymphoma Epidemiology in Spain (2017-2030)
  • Table 12: Natural Killer (NK)-Cell Lymphoma Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13: Natural Killer (NK)-Cell Lymphoma Epidemiology in the UK (2017-2030)
  • Table 14: Natural Killer (NK)-Cell Lymphoma Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15: Natural Killer (NK)-Cell Lymphoma Epidemiology in Japan (2017-2030)
  • Table 16: Natural Killer (NK)-Cell Lymphoma Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17: Drug Name, Clinical Trials by Recruitment status
  • Table 18: Drug Name, Clinical Trials by Zone
  • Table 19: Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20: Region-wise Market Size in USD, Million (2017-2030)
  • Table 21: 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22: United States Market Size in USD, Million (2017-2030)
  • Table 23: United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24: Germany Market Size in USD, Million (2017-2030)
  • Table 25: Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26: France Market Size in USD, Million (2017-2030)
  • Table 27: France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28: Italy Market Size in USD, Million (2017-2030)
  • Table 29: Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30: Spain Market Size in USD, Million (2017-2030)
  • Table 31: Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32: United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33: United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34: Japan Market Size in USD, Million (2017-2030)
  • Table 35: Japan Market Size by Therapy in USD, Million (2017-2030)

The list of tables is not exhaustive; the final content may vary

List of Figures

  • Figure 1: 7MM Natural Killer (NK)-Cell Lymphoma Epidemiology (2017-2030)
  • Figure 2: 7MM Natural Killer (NK)-Cell Lymphoma Diagnosed and Treatable Cases (2017-2030)
  • Figure 3: Natural Killer (NK)-Cell Lymphoma Epidemiology in the United States (2017-2030)
  • Figure 4: Natural Killer (NK)-Cell Lymphoma Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5: Natural Killer (NK)-Cell Lymphoma Epidemiology in Germany (2017-2030)
  • Figure 6: Natural Killer (NK)-Cell Lymphoma Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7: Natural Killer (NK)-Cell Lymphoma Epidemiology in France (2017-2030)
  • Figure 8: Natural Killer (NK)-Cell Lymphoma Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9: Natural Killer (NK)-Cell Lymphoma Epidemiology in Italy (2017-2030)
  • Figure 10: Natural Killer (NK)-Cell Lymphoma Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11: Natural Killer (NK)-Cell Lymphoma Epidemiology in Spain (2017-2030)
  • Figure 12: Natural Killer (NK)-Cell Lymphoma Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13: Natural Killer (NK)-Cell Lymphoma Epidemiology in the UK (2017-2030)
  • Figure 14: Natural Killer (NK)-Cell Lymphoma Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15: Natural Killer (NK)-Cell Lymphoma Epidemiology in Japan (2017-2030)
  • Figure 16: Natural Killer (NK)-Cell Lymphoma Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17: Drug Name, Clinical Trials by Recruitment status
  • Figure 18: Drug Name, Clinical Trials by Zone
  • Figure 19: Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20: Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21: 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22: United States Market Size in USD, Million (2017-2030)
  • Figure 23: United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24: Germany Market Size in USD, Million (2017-2030)
  • Figure 25: Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26: France Market Size in USD, Million (2017-2030)
  • Figure 27: France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28: Italy Market Size in USD, Million (2017-2030)
  • Figure 29: Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30: Spain Market Size in USD, Million (2017-2030)
  • Figure 31: Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32: United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33: United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34: Japan Market Size in USD, Million (2017-2030)
  • Figure 35: Japan Market Size by Therapy in USD, Million (2017-2030)

The list of figures is not exhaustive; the final content may vary.

目次
Product Code: DIMI1111

DelveInsight's "Natural Killer (NK)-Cell Lymphoma - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Natural Killer (NK)-Cell Lymphoma , historical and forecasted epidemiology as well as the Natural Killer (NK)-Cell Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Natural Killer (NK)-Cell Lymphoma market report provides current treatment practices, emerging drugs, Natural Killer (NK)-Cell Lymphoma market share of the individual therapies, current and forecasted Natural Killer (NK)-Cell Lymphoma market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Natural Killer (NK)-Cell Lymphoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Natural Killer (NK)-Cell Lymphoma Disease Understanding and Treatment Algorithm

The DelveInsight Natural Killer (NK)-Cell Lymphoma market report gives a thorough understanding of the Natural Killer (NK)-Cell Lymphoma by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Natural Killer (NK)-Cell Lymphoma .

Treatment

It covers the details of conventional and current medical therapies available in the Natural Killer (NK)-Cell Lymphoma market for the treatment of the condition. It also provides Natural Killer (NK)-Cell Lymphoma treatment algorithms and guidelines in the United States, Europe, and Japan.

Natural Killer (NK)-Cell Lymphoma Epidemiology

The Natural Killer (NK)-Cell Lymphoma epidemiology division provide insights about historical and current Natural Killer (NK)-Cell Lymphoma patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Natural Killer (NK)-Cell Lymphoma epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Natural Killer (NK)-Cell Lymphoma Epidemiology

The epidemiology segment also provides the Natural Killer (NK)-Cell Lymphoma epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Natural Killer (NK)-Cell Lymphoma Drug Chapters

Drug chapter segment of the Natural Killer (NK)-Cell Lymphoma report encloses the detailed analysis of Natural Killer (NK)-Cell Lymphoma marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Natural Killer (NK)-Cell Lymphoma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Natural Killer (NK)-Cell Lymphoma treatment.

Natural Killer (NK)-Cell Lymphoma Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Natural Killer (NK)-Cell Lymphoma treatment.

Natural Killer (NK)-Cell Lymphoma Market Outlook

The Natural Killer (NK)-Cell Lymphoma market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Natural Killer (NK)-Cell Lymphoma market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Natural Killer (NK)-Cell Lymphoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Natural Killer (NK)-Cell Lymphoma market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Natural Killer (NK)-Cell Lymphoma market in 7MM.

The United States Market Outlook

This section provides the total Natural Killer (NK)-Cell Lymphoma market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Natural Killer (NK)-Cell Lymphoma market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Natural Killer (NK)-Cell Lymphoma market size and market size by therapies in Japan is also mentioned.

Natural Killer (NK)-Cell Lymphoma Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Natural Killer (NK)-Cell Lymphoma market or expected to get launched in the market during the study period 2017-2030. The analysis covers Natural Killer (NK)-Cell Lymphoma market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Natural Killer (NK)-Cell Lymphoma Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Natural Killer (NK)-Cell Lymphoma key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Natural Killer (NK)-Cell Lymphoma emerging therapies.

Reimbursement Scenario in Natural Killer (NK)-Cell Lymphoma

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Natural Killer (NK)-Cell Lymphoma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Natural Killer (NK)-Cell Lymphoma market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Natural Killer (NK)-Cell Lymphoma Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of Natural Killer (NK)-Cell Lymphoma , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Natural Killer (NK)-Cell Lymphoma epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Natural Killer (NK)-Cell Lymphoma are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Natural Killer (NK)-Cell Lymphoma market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Natural Killer (NK)-Cell Lymphoma market

Report Highlights:

  • In the coming years, Natural Killer (NK)-Cell Lymphoma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Natural Killer (NK)-Cell Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Natural Killer (NK)-Cell Lymphoma . Launch of emerging therapies will significantly impact the Natural Killer (NK)-Cell Lymphoma market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Natural Killer (NK)-Cell Lymphoma
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Natural Killer (NK)-Cell Lymphoma Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Natural Killer (NK)-Cell Lymphoma Pipeline Analysis
  • Natural Killer (NK)-Cell Lymphoma Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Natural Killer (NK)-Cell Lymphoma Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Natural Killer (NK)-Cell Lymphoma Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Natural Killer (NK)-Cell Lymphoma Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What was the Natural Killer (NK)-Cell Lymphoma market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Natural Killer (NK)-Cell Lymphoma total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Natural Killer (NK)-Cell Lymphoma market size during the forecast period (2017-2030)?
  • At what CAGR, the Natural Killer (NK)-Cell Lymphoma market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Natural Killer (NK)-Cell Lymphoma market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Natural Killer (NK)-Cell Lymphoma market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Natural Killer (NK)-Cell Lymphoma ?
  • What is the historical Natural Killer (NK)-Cell Lymphoma patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Natural Killer (NK)-Cell Lymphoma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Natural Killer (NK)-Cell Lymphoma ?
  • Out of all 7MM countries, which country would have the highest prevalent population of Natural Killer (NK)-Cell Lymphoma during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Natural Killer (NK)-Cell Lymphoma treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Natural Killer (NK)-Cell Lymphoma in the USA, Europe, and Japan?
  • What are the Natural Killer (NK)-Cell Lymphoma marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Natural Killer (NK)-Cell Lymphoma ?
  • How many therapies are developed by each company for Natural Killer (NK)-Cell Lymphoma treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Natural Killer (NK)-Cell Lymphoma treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Natural Killer (NK)-Cell Lymphoma therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Natural Killer (NK)-Cell Lymphoma and their status?
  • What are the key designations that have been granted for the emerging therapies for Natural Killer (NK)-Cell Lymphoma ?
  • What are the global historical and forecasted market of Natural Killer (NK)-Cell Lymphoma ?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Natural Killer (NK)-Cell Lymphoma market
  • To understand the future market competition in the Natural Killer (NK)-Cell Lymphoma market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Natural Killer (NK)-Cell Lymphoma in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Natural Killer (NK)-Cell Lymphoma market
  • To understand the future market competition in the Natural Killer (NK)-Cell Lymphoma market

Table of Contents

1. Key Insights

2. Executive Summary of Natural Killer (NK)-Cell Lymphoma

3. Competitive Intelligence Analysis for Natural Killer (NK)-Cell Lymphoma

4. Natural Killer (NK)-Cell Lymphoma : Market Overview at a Glance

  • 4.1. Natural Killer (NK)-Cell Lymphoma Total Market Share (%) Distribution in 2017
  • 4.2. Natural Killer (NK)-Cell Lymphoma Total Market Share (%) Distribution in 2030

5. Natural Killer (NK)-Cell Lymphoma : Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Natural Killer (NK)-Cell Lymphoma Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Natural Killer (NK)-Cell Lymphoma Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Natural Killer (NK)-Cell Lymphoma Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Natural Killer (NK)-Cell Lymphoma Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Natural Killer (NK)-Cell Lymphoma Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Natural Killer (NK)-Cell Lymphoma Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Natural Killer (NK)-Cell Lymphoma Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Natural Killer (NK)-Cell Lymphoma Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Natural Killer (NK)-Cell Lymphoma Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Natural Killer (NK)-Cell Lymphoma Treatment and Management
  • 8.2. Natural Killer (NK)-Cell Lymphoma Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Natural Killer (NK)-Cell Lymphoma Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Natural Killer (NK)-Cell Lymphoma : Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Natural Killer (NK)-Cell Lymphoma Market Size in 7MM
  • 13.3. Natural Killer (NK)-Cell Lymphoma Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Natural Killer (NK)-Cell Lymphoma Total Market Size in the United States
    • 15.1.2. Natural Killer (NK)-Cell Lymphoma Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Natural Killer (NK)-Cell Lymphoma Total Market Size in Germany
    • 15.3.2. Natural Killer (NK)-Cell Lymphoma Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Natural Killer (NK)-Cell Lymphoma Total Market Size in France
    • 15.4.2. Natural Killer (NK)-Cell Lymphoma Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Natural Killer (NK)-Cell Lymphoma Total Market Size in Italy
    • 15.5.2. Natural Killer (NK)-Cell Lymphoma Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Natural Killer (NK)-Cell Lymphoma Total Market Size in Spain
    • 15.6.2. Natural Killer (NK)-Cell Lymphoma Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Natural Killer (NK)-Cell Lymphoma Total Market Size in the United Kingdom
    • 15.7.2. Natural Killer (NK)-Cell Lymphoma Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Natural Killer (NK)-Cell Lymphoma Total Market Size in Japan
    • 15.8.3. Natural Killer (NK)-Cell Lymphoma Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Natural Killer (NK)-Cell Lymphoma

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

The table of contents is not exhaustive; the final content may vary.

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.